| Nov 20 |
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
|
| Nov 19 |
Ocugen reports positive data for OCU400, OCU410
|
| Nov 19 |
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
|
| Nov 14 |
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 14 |
Ocugen: Q3 Earnings Snapshot
|
| Nov 9 |
Q3 2024 Ocugen Inc Earnings Call
|
| Nov 9 |
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
| Nov 8 |
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Ocugen reports Q3 results
|
